AXONIS THERAPEUTICS, INC.
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibition within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University. We are an exceptional team of drug hunters and target biology experts who have built a proprietary KCC2 discovery engine based on several years of world-leading know-how, to become the leaders in... this potential blockbuster drug space. A venBio portfolio company, Axonis has raised $34+M in dilutive Seed funding, and $8+M in competitive non-dilutive grants/awards, to support our mission of improving the lives of people suffering from neurological disorders. First-in-human trials will begin in 2024 for the first-in-class oral KCC2 potentiator drug, AXN-027, designed for fine-tuning inhibition to treat epilepsy, pain and other CNS pathologies.
AXONIS THERAPEUTICS, INC.
Industry:
Biotechnology Medical
Founded:
2020-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.axonis.us
Total Employee:
11+
Status:
Active
Contact:
(617) 221-5364
Total Funding:
14.6 M USD
Technology used in webpage:
U.S. Server Location
Similar Organizations
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Enterin
Philadelphia-based biotechnology company .
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
SYNGAP RESEARCH FUND
SYNGAP RESEARCH FUND investment in Grant - Axonis Therapeutics, Inc.
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Axonis Therapeutics, Inc.
National Eye Institute
National Eye Institute investment in Grant - Axonis Therapeutics, Inc.
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Axonis Therapeutics, Inc.
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Axonis Therapeutics, Inc.
BoxOne Ventures
BoxOne Ventures investment in Seed Round - Axonis Therapeutics, Inc.
Civilization Ventures
Civilization Ventures investment in Seed Round - Axonis Therapeutics, Inc.
Alexandria Venture Investments
Alexandria Venture Investments investment in Seed Round - Axonis Therapeutics, Inc.
R3 Asset Management Pte Ltd
R3 Asset Management Pte Ltd investment in Seed Round - Axonis Therapeutics, Inc.
Milad Alucozai
Milad Alucozai investment in Seed Round - Axonis Therapeutics, Inc.
Official Site Inspections
http://www.axonis.us Semrush global rank: 7.44 M Semrush visits lastest month: 768
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Axonis Therapeutics, Inc."
Home | Neuro-Focused Biotechnology | KCC2
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibition within the brain, by translating breakthrough discoveries spun out …See details»
Axonis Therapeutics - Crunchbase Company Profile & Funding
9,806 Number of Organizations • $705.9B Total Funding Amount • 50,020 Number of Investors. Track . Show More . ... Axonis Therapeutics is located in Boston, Massachusetts, United …See details»
Space-Grown Brain Organoids Help Advance New Neurological …
Nov 21, 2024 Axonis recently announced the completion of a successful $115 million Series A financing campaign that was oversubscribed (the company received investor interest beyond …See details»
Platform & Pipeline | AXONIS Therapeutics
Contact us. Our Science. ... Axonis’ lead candidate AXN-027 is a first- and best-in-class oral KCC2-potentiating drug currently being evaluated in a Phase 1 clinical trial, and is being …See details»
Axonis Therapeutics Company Profile 2024: Valuation, …
Axonis Therapeutics’s primary industry is Drug Discovery. Is Axonis Therapeutics a private or public company? Axonis Therapeutics is a Private company. What is Axonis Therapeutics’s current revenue? The current revenue for Axonis …See details»
Contact Us | AXONIS Therapeutics
Axonis Therapeutics, Inc. 75 Kneeland Street, 14th Fl. Boston, MA 02111 LinkedinSee details»
From Viral Villain to Gene Therapy Hero: Assembling 3D Brain …
Nov 13, 2024 Axonis advisor Zhigang He at Harvard University discovered there are also intrinsic mechanisms within CNS neurons that play a key role in preventing axon regeneration. …See details»
Axonis - Products, Competitors, Financials, Employees, …
Axonis is a biotechnology company focusing on the development of neuromedicines targeting the KCC2 protein, which plays a critical role in brain inhibition. The company is engaged in …See details»
Axonis Executive Summary - National Institute of Neurological …
AXONIS Therapeutics is advancing breakthrough drug discoveries to develop first-in-class therapeutics for neurological disorders, to make a real difference for patients, their families, …See details»
Axonis Therapeutics Announces $115 Million Series A Financing
Oct 30, 2024 Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 …See details»
Space research accelerates gene therapy for neurological disorders
Nov 22, 2024 Space research accelerates gene therapy for neurological disorders by Clarence Oxford Los Angeles CA (SPX) Nov 22, 2024 Biotechnology startup Axonis Therapeutics has …See details»
RePORT 〉 RePORTER - National Institutes of Health
Awardee Organization AXONIS THERAPEUTICS, INC. Description. Abstract Text. ... (SCI), despite roughly 17,000 people suffering SCI per year and about 300,000 people living with …See details»
Axonis Therapeutics Announces $115 Million Series A Financing
About Axonis Therapeutics. Axonis Therapeutics is a neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory …See details»
Award - SBIR
Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ... therapy alleviating neuropathic pain …See details»
AXONIS Therapeutics Announces $5 Million in Funding
Jul 14, 2021 AXONIS Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, committed to advancing breakthrough drug discoveries to develop first-in-class therapies for …See details»
RePORT 〉 RePORTER - National Institutes of Health
AXONIS Therapeutics is advancing a first-in- class oral KCC2 enhancer drug, AXN-006-01-3, towards clinic with GLP-toxicology studies planned for Q4 2022. In this Phase 1 SBIR …See details»
News | AXONIS Therapeutics
Oct 8, 2020 Axonis Therapeutics Announces $115 Million Series A Financing — Oversubscribed financing brings together leading syndicate of life sciences investors — Read More » October …See details»
RePORT 〉 RePORTER
AXONIS’ are developing proprietary compounds that selectively potentiate KCC2 function by binding to KCC2, increasing KCC2 surface clustering, and increasing KCC2 chloride extrusion. …See details»
News Archives | AXONIS Therapeutics
Oct 30, 2024 Contact us. News. News Axonis Therapeutics Announces $115 Million Series A Financing. Sharon Reaves / October 30, 2024 . Axonis Therapeutics Announces $115 Million …See details»
Our Approach | AXONIS Therapeutics | KCC2
A diverse variety of neuron subtypes interact in complex wiring circuits, execute functions that are region-specific, and closely interact with other cell types and organ systems (e.g., immune …See details»